Abstract
The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axillas. With the increased use of SLNB in women who present with breast carcinoma, the role of completion ALND for a positive sentinel lymph node has been challenged. We review the literature available and discuss future directions in identifying a subgroup who may avoid an ALND.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 195-198 |
| Number of pages | 4 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 8 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2008 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Axillary node dissection
- Breast cancer
- Sentinel node biopsy
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Is axillary dissection needed in node-positive breast cancer?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS